Amplia Therapeutics Limited ATX.AX · Stock Open Amplia Therapeutics Limited in new tab
Amplia Therapeutics Limited Analysis (ATX.AX)
Is Amplia Therapeutics Limited a good investment? Amplia Therapeutics Limited (ATX.AX) is currently trading at 0.1250 AUD.
Earnings Schedule: Amplia Therapeutics Limited is expected to release its next earnings report on Nov. 27, 2026. The market consensus estimate for Forward EPS is -0.01.
Investor FAQ
Does Amplia Therapeutics Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Amplia Therapeutics Limited?
Amplia Therapeutics Limited is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 27, 2026. The company currently has a trailing EPS of -0.02.
Company Profile
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
| Split Date | Split Ratio to 1 |
|---|---|
| June 15, 2016 | 1.01 |
| April 30, 2018 | 1:10 |
| July 3, 2020 | 1.08 |
| April 19, 2024 | 1.03 |
Community Discussion